Study of evaluating therapeutic efficacy of intravitreal methotrexate in patients with primary intraocular lymphoma

Study of evaluating therapeutic efficacy of intravitreal methotrexate in patients with primary intraocular lymphoma - Evaluation of therapeutic efficacy of intravitreal MTX in patients with PIOL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032121

Enrollment

Registered

2018-04-10

Start date

2018-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary intraocular lymphoma

Interventions

Patients receive 0.1ml of MTX (diluted to a concentration of 400ug/0.1ml using saline) by intravitreal injection. MTX is administrated twice a week for 4 weeks, after that once a week for 4 weeks, a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with primary intraocular lymphoma

Exclusion criteria

Exclusion criteria: 1. performance status 4 2. patients who participated in other clinical trials within three months 3. patients with severe allergy to MTX 4. patients who desire for childbearing 5. patients with severe dementia or psychiatric disorder 6. Patients suggested as ineligible by their attending physician

Design outcomes

Primary

Measure	Time frame
Systemic and ophthalmological adverse effects and frequency	—

Secondary

Measure	Time frame
1. frequency of intraocular recurrences 2. recurrence-free survival 3. response rate	—

Countries

Japan

Contacts

Public ContactYuko Takemoto

Kanazawa University Hospital Department of opthalmology and visual science

yuko-t@med.kanazawa-u.ac.jp076-265-2403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026